Miyoung Kim

发表

LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

K. O'Byrne, T. Mok, E. Tan, 2015 .

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Keunchil Park, E. Cho, Joo‐Hang Kim, 2021, BMC Cancer.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

G. Scagliotti, N. Pavlakis, T. Nakano, 2019, The Lancet. Respiratory medicine.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

P. Jänne, S. Ou, Keunchil Park, 2016 .

Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2014, The oncologist.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2015, The Oncologist.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.